. Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma. Hematol Oncol Stem Cell Ther. 2021.
Main menu
- About
- Chapters
- Cellular and nuclear reprogramming
- Ectoderm specification and differentiation
- Endoderm specification and differentiation
- Epigenetics
- Genomics and proteomics
- Germ cell and somatic stem cell biology in reproduction
- Manufacturing
- Mesoderm specification and differentiation
- Niche biology, homing, and migration
- Renewal
- Stem cell immunology
- Therapeutic prospects
- Tissue engineering
- Protocols
- StemLabs
- News & Profiles
- Journal Stream
- Forum